Wilex AG (WL6) - Financial and Strategic SWOT Analysis Review

May 2017 | 55 pages | ID: WFE9F8549D1EN
GlobalData

Abstracts

Wilex AG (WL6) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Wilex AG (Wilex) is a biopharmaceutical company with a focus on cancer. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. It develops products based on and small molecules and antibodies, which are offered for out-licensing. Wilex’s pipeline products are focused at treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non

metastatic ccRCC, kidney cancers and solid tumors. Heidelberg Pharma GmbH (Heidelberg), Wilex’s subsidiary provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg focuses on the development of a proprietary ADC technology. Wilex is headquartered in Munich, Germany.

Wilex AG Key Recent Developments

Apr 12,2017: WILEX: Interim management statement on the first three months of 2017
Mar 30,2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business
Oct 13,2016: WILEX: Interim Management Statement on the First Nine Months of 2016
Jul 14,2016: WILEX publishes Half-yearly Financial Report
Jun 14,2016: Advanced Proteome Therapeutics and Heidelberg Pharma collaborate to create improved cancer therapeutics

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Wilex AG - Key Facts
Wilex AG - Key Employees
Wilex AG - Key Employee Biographies
Wilex AG - Major Products and Services
Wilex AG - Pharmaceutical Pipeline Products Data
Wilex AG, Pipeline Products by Therapy Area
Wilex AG, Pipeline Products by Development Phase
Wilex AG - History
Wilex AG - Company Statement
Wilex AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Wilex AG - Business Description
Wilex AG - Corporate Strategy
Wilex AG - SWOT Analysis
SWOT Analysis - Overview
Wilex AG - Strengths
Wilex AG - Weaknesses
Wilex AG - Opportunities
Wilex AG - Threats
Wilex AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Wilex AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Wilex AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Wilex AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017
Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business
Oct 13, 2016: WILEX: Interim Management Statement on the First Nine Months of 2016
Jul 14, 2016: WILEX publishes Half-yearly Financial Report
Jun 14, 2016: Advanced Proteome Therapeutics and Heidelberg Pharma collaborate to create improved cancer therapeutics
Jun 02, 2016: WILEX announces change on the Executive Management Board
Apr 14, 2016: WILEX AG: Interim management statement on the first quarter of 2016
Apr 06, 2016: WILEX plans change on the Supervisory Board
Mar 22, 2016: WILEX announces financial figures for the 2015 financial year and reports on course of business
Feb 02, 2016: WILEX: US-patent office granted patent for amatoxin conjugates for tumour therapy

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Wilex AG, Key Facts
Wilex AG, Key Employees
Wilex AG, Key Employee Biographies
Wilex AG, Major Products and Services
Wilex AG, Number of Pipeline Products by Therapy Area
Wilex AG, Number of Pipeline Products by Development Stage
Wilex AG, History
Wilex AG, Subsidiaries
Wilex AG, Key Competitors
Wilex AG, Ratios based on current share price
Wilex AG, Annual Ratios
Wilex AG, Annual Ratios (Cont.1)
Wilex AG, Interim Ratios
Wilex AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Wilex AG, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Wilex AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Wilex AG, Pipeline Products by Therapy Area
Wilex AG, Pipeline Products by Development Phase
Wilex AG, Performance Chart (2012 - 2016)
Wilex AG, Ratio Charts
Wilex AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Wilex AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

U3 Pharma GmbH
Scil Proteins GmbH
Merck KGaA
MediGene AG
Epigenomics AG
Biotest AG
Baxter Oncology GmbH
4SC AG